4 completed, 1 recruiting, 1 withdrawn. 6 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow peramivir: new trials by email Literature Review of peramivir trials Research Report on peramivir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza Oseltamivir, Favipiravir, Zanamivir - Influenza, Influenza, Human | Phase 2 | Recruiting | University of Oxford | 3000 | 2023-02-22 | 2026-04-14 |
| Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections Peramivir - Influenza | Phase 2 / Phase 3 | Completed | Chinese University of Hong Kong | 16 | 2011-02-01 | 2016-01-29 |
| A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza Peramivir, Placebo - Acute, Uncomplicated Human Influenza | Phase 2 | Completed | BioCryst Pharmaceuticals | 405 | 2008-07-01 | 2015-02-16 |
| Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza Peramivir 200 mg, Peramivir 400 mg, Oseltamivir - Influenza | Phase 2 | Completed | BioCryst Pharmaceuticals | 137 | 2007-07-01 | 2015-02-12 |
| Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza. Peramivir 150 mg, Peramivir 300 mg, Placebo - Influenza | Phase 2 | Completed | BioCryst Pharmaceuticals | 344 | 2007-01-01 | 2015-02-12 |
| Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza Peramivir - Influenza | Phase 1 / Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2011-11-11 |
Influenza, Human (5)
BioCryst Pharmaceuticals (3) · Chinese University of Hong Kong (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University of Oxford (1)
United States (4) · Australia (2) · Canada (2) · New Zealand (2) · South Africa (2) · Brazil (1) · China (1) · Hong Kong (1) · Laos (1) · Nepal (1) · Singapore (1) · Thailand (1)
Alain Martel, MD (1) · Allan Kelly, MD (1) · Balbir Chahal, MD (1) · Barry Packman, MD (1) · Ben Lasko, MD (1) · Bernardo Ng, MD (1) · Bruce Berwald, MD (1) · Bruce D. Forney, MD (1) · Chivers Woodruff, Jr., MD (1) · Dan C Henry, MD (1) · Daniel Shu, MD (1) · David L. Fried, MD (1) · David Parenti, MD (1) · Dennis Mikolich, MD (1) · Dennis Riff, MD (1)
N01AI30025 (1)